1. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, et al.; American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–e327.
  2. Dickstein K, Cohen-Solal A, et al.; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–89.
  3. Yancy CW, Jessup M, Bozkurt B, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–e239.
  4. Hunt SA, Abraham WT, Chin MH, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:1825–52.
  5. Milne EN. Correlation of physiologic ?ndings with chest roentgenology. Radiol Clin North Am 1973;11:17–47.
  6. Aytemur Solak Z, Gündüz Telli C, Kabaroğlu C, Doğan B, Bayındır Ü, Erdener D. Pulmoner emboli tanısında D-dimer testinin yeri. Solunum Hastalıkları Dergisi 2003;14:11–6.
  7. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825–32.
  8. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202–9.
  9. Wang R, Cao Z, Li Y, Yu K. Utility of N-terminal pro B-type natriuretic peptide and mean platelet volume in differentiating congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol 2013;170:e28–e9.
  10. Bozkanat E, Tozkoparan E, Baysan O, Deniz O, Ciftci F, Yokusoglu M. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res 2005;33:537–44.
  11. Corsonello A, Antonelli Incalzi R, Pistelli R, Pedone C, Bustacchini S, Lattanzio F. Comorbidities of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 2011;17 Suppl 1:S21–S8.
  12. Render ML, Weinstein AS, Blaustein AS. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest 1995;107:162–8.
  13. McCullough PA, Hollander JE, Nowak RM, et al.; BNP Multinational Study Investigators. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003;10: 198–204.
  14. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887–94.
  15. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8: 706–11.
  16. Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res 2013;162:208–18.
  17. Georgiopoulou VV, Kalogeropoulos AP, Psaty BM, et al. Lung function and risk for heart failure among older adults: the Health ABC Study. Am J Med 2011;124:334–41.
  18. Engström G, Melander O, Hedblad B. Population-based study of lung function and incidence of heart failure hospitalisations. Thorax 2010;65:633–8.
  19. Rutten FH, Hoes AW. Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects? Eur J Heart Fail 2012;14:348–50.
  20. Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118:981–9.
  21. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63–70.
  22. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodríguez-González Moro JM, et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. [Article in Spanish] Arch Bronconeumol 2008; 238:233–8.
  23. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006;61:772–8.
  24. Wheaton AG, Ford ES, Cunningham TJ, Croft JB. Chronic obstructive pulmonary disease, hospital visits, and comorbidities: National Survey Of Residential Care Facilities, 2010. J Aging Health 2015;27:480–99.
  25. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–9.
  26. Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail 2012;14:395–403.
  27. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from ‘diastolic heart failure’ or from misdiagnosis? A prospective descriptive study. BMJ 2000; 321:215–8.
  28. Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005;331(7529):1379.
  29. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710–8.
  30. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004;126: 1330–6.
  31. Kandis H, Ozhan H, Ordu S, et al. The prognostic value of mean platelet volume in decompensated heart failure. Emerg Med J 2011;28: 575–8.
  32. Wang R, Cao Z, Li Y, Yu K. Mean platelet volume provides an additive value in differentiating congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol 2015;179:201– 2.
  33. Yoshihisa A, Takiguchi M, Shimizu T, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014; 64:256–64.
  34. Faggiano P. Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol 1994;44:1–8.
  35. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964–9.
  36. Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure – COPD or congestion? Int J Cardiol 2013;168:1910–6.
  37. Boschetto P, Fucili A, Stendardo M, et al, Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 2013;18:125–30.
  38. Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail 2007; 9:292–9.
  39. Dickstein K, Cohen-Solal A, Filippatos G, et al.; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–42.
  40. Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart 2011;97:411–6.
  41. Lainscak M, Anker SD. Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. Herz 2009;34:141–7.
  42. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013;1:73–83.
  43. Bartziokas K, Papaioannou AI, Minas M, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther 2011;24:625–31.
  44. Lainscak M, Majc Hodoscek M, Dungen HD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009;121: 309–13.
  45. Sarc I, Jeric T, Ziherl K, et al. Adherence to treatment guidelines and long-term survival in hospitalized patients with chronic obstructive pulmonary disease. J Eval Clin Pract 2011;17: 737–43.
  46. Packard KA, Wurdeman RL, Arouni AJ. ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother 2002;36:1058-67.
  47. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543–51.
  48. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10:45.
  49. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554–60.
  50. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005;91:907–13.
  51. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977–84.
  52. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880–7.
  53. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O’Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013;111:582–7.
  54. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012;12:48.
  55. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428–33.
  56. Salpeter S, Ormiston T, Salpeter E. Cardiose-lective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD003566.
  57. Loth DW, Brusselle GG, Lahousse L, Hofman A, Leufkens HG, Stricker BH. Beta-adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study. Br J Clin Pharmacol 2014;77:190–200.
  58. Packer M, Fowler MB, Roecker EB, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194–9.
  59. Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci 2014;10:920–32.
  60. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013;34:2795–803.
  61. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med 2011;40:135– 45.
  62. Bermingham M, O’Callaghan E, Dawkins I, et al. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 2011; 13:885–91.
  63. Zeng LH(1), Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging 2013;8:1157– 65.
  64. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010; 137:13–9.
  65. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20–30.
  66. Anthonisen MNR, Connett JE, Enright PF, Manfreda J; Lung Health Study Research Group. Hospitalization and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333–9.
  67. Huiart L, Ernst P, Ranouil X, Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006;13:134–8.
  68. Emerman CL, Safety and efficacy of nesiritide for the treatment of decompensated heart failure. Rev Cardiovasc Med 2002;3 Suppl 4:S28– 34.